Research programme: urokinase inhibitors - Wilex/4SCAlternative Names: Urokinase inhibitors research programme - Wilex/4SC
Latest Information Update: 22 Feb 2005
At a glance
- Originator 4SC; Wilex
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Jun 2002 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 14 Jan 2002 Preclinical development for Cancer in Germany (unspecified route)